Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

McKinsey's Overlapping Work For FDA, Opioid Makers Raises Conflict Of Interest Questions

Executive Summary

A House Oversight and Reform Committee report says McKinsey consultants advised the FDA on modernization of its new drugs regulatory program, the Sentinel Initiative, and other projects at the same time it was working for opioid manufacturers on related topics; agency says McKinsey did not inform it of potential conflicts of interest.

You may also be interested in...



Will US FDA Change Its Conflict Of Interest Policies In Wake Of McKinsey’s Work With Purdue?

House Oversight Committee members grill McKinsey global managing partner about whether the firm told FDA about its simultaneous work for opioid maker Purdue. Agency says it does not anticipate future contracts with McKinsey until investigations are completed.

US FDA’s New ‘Integrated’ Review Process Starts To Win Over Skeptics, But Industry Still Wants More Details

In an interview with the Pink Sheet, implementation director Rhonda Hearns-Stewart says FDA has modified the template for its 'integrated assessment' of marketing applications in response to feedback from reviewers and sponsors.

McKinsey’s Push For Class-Wide Opioid REMS Among Actions Targeted In Opioid Settlement

Consulting firm agrees to turn over tens of thousands of documents detailing its advice to Purdue, J&J, Endo and Mallinckrodt and pay $537m as part of a deal with 47 states.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel